Chinook Therapeutics (Chinook Therapeutics) Long-Term Debt : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Chinook Therapeutics Long-Term Debt?

Chinook Therapeutics's Long-Term Debt for the quarter that ended in Jun. 2023 was $0.00 Mil.

Chinook Therapeutics Long-Term Debt Historical Data

The historical data trend for Chinook Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chinook Therapeutics Long-Term Debt Chart

Chinook Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Long-Term Debt

Chinook Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Long-Term Debt	Get a 7-Day Free Trial											-	-	-	-	-

Chinook Therapeutics (NAS:KDNY) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Chinook Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Chinook Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Chinook Therapeutics (Chinook Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chinook Therapeutics Inc (NAS:KDNY) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Fairview Avenue North, Suite 900, Seattle, WA, USA, 98109

Website

https://www.chinooktx.com

Chinook Therapeutics Inc is a clinical-stage biotechnology company. The products of the company are focused on rare, severe chronic kidney disorders. The clinical program is atrasentan, a potent and selective endothelin A receptor antagonist and currently conducting the phase 3 ALIGN trial of atrasentan for IgA nephropathy (IgAN) and the phase 2 AFFINITY basket trial for proteinuric glomerular diseases. The second product candidate, BION-1301, is an anti-APRIL monoclonal antibody and the third product candidate is CHK-336, an oral small-molecule LDHA inhibitor for the treatment of primary and idiopathic hyperoxaluria. It is incorporated in Delaware and is headquartered in Seattle, Washington.

Executives

Andrew James King	officer: Head of Renal Discovery	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
William Mariner Greenman	director	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Eric Dobmeier	director, officer: President, CEO	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Mahesh Krishnan	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Andrew Oxtoby	officer: Chief Commercial Officer	8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Tom Frohlich	officer: Chief Business Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Alan Glicklich	officer: Chief Medical Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Versant Voyageurs I, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104